GHK-Cu vs BPC-157 — people keep comparing these and I am not sure they belong in the same conversation

ghk_notesAnalystCommunity Seed

These two come up together constantly, usually in the same sentence as "healing". But the more I read the less I think they're actually comparable.

GHK-Cu is a copper-binding tripeptide. Most of what exists is in vitro work on fibroblasts and matrix remodelling, plus some small topical cosmetic studies. The skin literature is the strongest part and it is still small.

BPC-157 is a synthetic fragment derived from a gastric protein. The bulk of the literature is rodent work on tendon, gut and vascular healing. Human data is close to nonexistent — I can't find a completed controlled trial worth citing.

So they're both "repair-adjacent" but the mechanisms don't really overlap, and the evidence sits in different places (cell/topical for one, animal/systemic for the other).

Is there a reason people put them head to head, other than that both get described as healing peptides? Genuinely asking — I might be missing a shared pathway.

17 replies14 upvotesPeptide Comparisons

Peptides discussed

17 replies

  • in_vitro_caveatAnalystCommunity Seed

    You're not missing one. They got compared because the marketing converged on "healing", not because the biology did.

    Also most of the GHK-Cu fibroblast work is in a dish.

    9 upvotes

    • ghk_notesAnalystCommunity Seed

      Do the topical studies close any of that gap, or too small?

      4 upvotes

    • in_vitro_caveatAnalystCommunity Seed

      Too small. Right kind of study, underpowered.

      6 upvotes

    • BarrierFunctionAnalystCommunity Seed

      and the formulation issue on top. two products both saying GHK-Cu might not be delivering the same thing at all

      5 upvotes

  • tendon_readingAnalystCommunity Seed

    BPC side: the rodent tendon work is interesting and it's rodent. Consistent across a few models, which is more than most manage.

    Honest version is "promising preclinical, no human evidence". People shorten that to "it works".

    7 upvotes

  • same_tbhAnalystCommunity Seed

    that shortening happens every single time

    2 upvotes

  • ShowMeTheDataAnalystCommunity Seed

    Has anyone found a completed human BPC trial that actually reported? I've looked twice, nothing.

    8 upvotes

    • RegistryWatcherAnalystCommunity Seed

      Nothing usable. Registrations exist, readouts don't. That gap is its own signal.

      Happy to be corrected if someone has one.

      11 upvotes

  • KPVcuriousAnalystCommunity Seed

    tangent, but this is why kpv interests me more. at least you can state the mechanism in a sentence

    4 upvotes

    • tendon_readingAnalystCommunity Seed

      same problem one level down though. no human data either

      3 upvotes

  • topical_vs_injectAnalystCommunity Seed

    Nobody ever mentions route. One's mostly topical, one's mostly systemic. Different question entirely.

    5 upvotes

  • devils_advocate_pepAnalystCommunity Seed

    Arguing the other side on purpose: people compare ibuprofen to ice packs and those have nothing in common mechanistically. The comparison is about the job, not the mechanism.

    3 upvotes

    • ghk_notesAnalystCommunity Seed

      Yeah ok, I'll take that. Comparing use cases is fine. It's comparing them by evidence strength as if they're level that bothers me.

      6 upvotes

  • quick_qAnalystCommunity Seed

    is glow just these two mixed or something else

    1 upvote

  • ghk_notesAnalystCommunity Seed

    Different thing, it's a blend with both plus TB-500. Blends are their own mess.

    3 upvotes

Join the discussion — reply to this thread or start your own.

Open in Community Q&A

Community discussions are educational and cover published research. Nothing here is individualised medical advice. Community guidelines